What is the economic value of PCSK9 inhibitors for primary prevention in patients with heterozygous FH?
Only 2 economic models have specifically examined the value provided by PCSK9 inhibitors for primary prevention in patients with heterozygous FH (Online Data found low value when PCSK9 inhibitors were used for FH ($503000 per QALY added), whereas the second modelS7.1-8 reported intermediate value (incremental cost-effectiveness ratio of $75900 per QALY added). Consequently, the value of PCSK9 inhibitor therapy in FH is uncertain.